# The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

> **NCT05995392** · EARLY_PHASE1 · UNKNOWN · sponsor: **Richard W Yee, MD** · enrollment: 30 (estimated)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** Topical spironolactone ophthalmic solution, 0.005 mg/cc
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05995392
- **Lead sponsor:** Richard W Yee, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08
- **Primary completion:** 2024-02
- **Final completion:** 2024-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05995392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05995392, "The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05995392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*